{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:02:13Z","timestamp":1788447733591,"version":"build-2803163510"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1097\/inf.0000000000000747","type":"journal-article","created":{"date-parts":[[2015,5,7]],"date-time":"2015-05-07T14:22:37Z","timestamp":1431008557000},"page":"851-857","source":"Crossref","is-referenced-by-count":19,"title":["Meconium Tenofovir Concentrations and Growth and Bone Outcomes in Prenatally Tenofovir Exposed HIV-Uninfected Children"],"prefix":"10.1097","volume":"34","author":[{"given":"Sarah K.","family":"Himes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia W.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise L.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Tassiopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Hazra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Kacanek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell B.","family":"Van Dyke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Rich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George K.","family":"Siberry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn A.","family":"Huestis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R3-13-20210202","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/QAD.0b013e328352d135","article-title":"Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants.","volume":"26","author":"Siberry","year":"2012","journal-title":"AIDS"},{"key":"R4-13-20210202","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00042560-200203010-00001","article-title":"Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta).","volume":"29","author":"Tarantal","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R5-13-20210202","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/00042560-199904010-00001","article-title":"Administration of 9-2-(R)-(phosphonomethoxy)propyladenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies.","volume":"20","author":"Tarantal","year":"1999","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"R6-13-20210202","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1128\/AAC.00350-08","article-title":"Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.","volume":"52","author":"Van Rompay","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"R7-13-20210202","first-page":"354908","article-title":"Tenofovir nephrotoxicity: 2011 update.","volume":"2011","author":"Fernandez-Fernandez","year":"2011","journal-title":"AIDS Res Treat"},{"key":"R9-13-20210202","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/INF.0b013e31827f4eff","article-title":"Tenofovir treatment duration predicts proteinuria in a multiethnic United States cohort of children and adolescents with perinatal HIV-1 infection.","volume":"32","author":"Purswani","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R10-13-20210202","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1468-1293.2009.00716.x","article-title":"Tenofovir-associated renal and bone toxicity.","volume":"10","author":"Woodward","year":"2009","journal-title":"HIV Med"},{"key":"R11-13-20210202","doi-asserted-by":"crossref","first-page":"e38377","DOI":"10.1371\/journal.pone.0038377","article-title":"Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.","volume":"7","author":"Haskelberg","year":"2012","journal-title":"PLoS One"},{"key":"R12-13-20210202","doi-asserted-by":"crossref","first-page":"e32445","DOI":"10.1371\/journal.pone.0032445","article-title":"Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial.","volume":"7","author":"Rasmussen","year":"2012","journal-title":"PLoS One"},{"key":"R13-13-20210202","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jpeds.2007.12.020","article-title":"Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus.","volume":"152","author":"Purdy","year":"2008","journal-title":"J Pediatr"},{"key":"R14-13-20210202","doi-asserted-by":"crossref","first-page":"E711","DOI":"10.1542\/peds.2005-2525","article-title":"Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: Impact on bone mineral density in HIV-infected children.","volume":"118","author":"Gafni","year":"2006","journal-title":"Pediatrics"},{"key":"R15-13-20210202","doi-asserted-by":"crossref","first-page":"e23688","DOI":"10.1371\/journal.pone.0023688","article-title":"Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco.","volume":"6","author":"Liu","year":"2011","journal-title":"PLoS One"},{"key":"R16-13-20210202","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/clpt.2008.201","article-title":"Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109).","volume":"85","author":"Hirt","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"R17-13-20210202","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/QAD.0000000000000112","article-title":"Interactions of tenofovir and tenofovir disoproxil fumarate with drug efflux transporters ABCB1, ABCG2, and ABCC2; role in transport across the placenta.","volume":"28","author":"Neumanova","year":"2014","journal-title":"AIDS"},{"key":"R18-13-20210202","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/QAI.0b013e3182a7adb2","article-title":"Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy.","volume":"64","author":"Ransom","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R19-13-20210202","doi-asserted-by":"crossref","first-page":"e001217","DOI":"10.1371\/journal.pmed.1001217","article-title":"Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.","volume":"9","author":"Gibb","year":"2012","journal-title":"PLoS Med"},{"key":"R20-13-20210202","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.3851\/IMP1909","article-title":"In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers.","volume":"16","author":"Vigano","year":"2011","journal-title":"Antivir Ther"},{"key":"R22-13-20210202","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/cid\/cit601","article-title":"Safety of tenofovir during pregnancy for the mother and fetus: a systematic review.","volume":"57","author":"Wang","year":"2013","journal-title":"Clin Infect Dis"},{"key":"R24-13-20210202","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0022-3476(94)70379-5","article-title":"Postmortem drug analysis of meconium in early-gestation human fetuses exposed to cocaine: clinical implications.","volume":"124","author":"Ostrea","year":"1994","journal-title":"J Pediatr"},{"key":"R25-13-20210202","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/ntr\/ntq068","article-title":"Nicotine and metabolites in meconium as evidence of maternal cigarette smoking during pregnancy and predictors of neonatal growth deficits.","volume":"12","author":"Gray","year":"2010","journal-title":"Nicotine Tob Res"},{"key":"R26-13-20210202","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1111\/j.1360-0443.2010.03097.x","article-title":"Prenatal methadone exposure, meconium biomarker concentrations and neonatal abstinence syndrome.","volume":"105","author":"Gray","year":"2010","journal-title":"Addiction"},{"key":"R27-13-20210202","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.jpeds.2012.10.045","article-title":"Prenatal tobacco exposure, biomarkers for tobacco in meconium, and neonatal growth outcomes.","volume":"162","author":"Himes","year":"2013","journal-title":"J Pediatr"},{"key":"R28-13-20210202","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/clpt.2008.156","article-title":"Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes.","volume":"84","author":"Kacinko","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R29-13-20210202","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1021\/ac303188j","article-title":"Development and validation of the first liquid chromatography-tandem mass spectrometry assay for simultaneous quantification of multiple antiretrovirals in meconium.","volume":"85","author":"Himes","year":"2013","journal-title":"Anal Chem"},{"key":"R30-13-20210202","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/QAD.0b013e32835a9b80","article-title":"Bone mineral density in children and adolescents with perinatal HIV infection.","volume":"27","author":"DiMeglio","year":"2013","journal-title":"AIDS"},{"key":"R34-13-20210202","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s10461-010-9705-0","article-title":"Substance use in HIV-Infected women during pregnancy: self-report versus meconium analysis.","volume":"14","author":"Tassiopoulos","year":"2010","journal-title":"AIDS Behav"},{"key":"R36-13-20210202","doi-asserted-by":"crossref","first-page":"18757","DOI":"10.7448\/IAS.16.1.18757","article-title":"The next generation of the World Health Organizations global antiretroviral guidance.","volume":"16","author":"Hirnschall","year":"2013","journal-title":"J Int AIDS Soc"},{"key":"R37-13-20210202","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1359\/jbmr.091022","article-title":"Different indices of fetal growth predict bone size and volumetric density at 4 years of age.","volume":"25","author":"Harvey","year":"2010","journal-title":"J Bone Miner Res"},{"key":"R40-13-20210202","doi-asserted-by":"crossref","first-page":"5914","DOI":"10.1128\/AAC.00544-11","article-title":"Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants.","volume":"55","author":"Flynn","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"R41-13-20210202","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/QAI.0b013e3182a921eb","article-title":"Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life.","volume":"65","author":"Mirochnick","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R42-13-20210202","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1124\/mol.106.028233","article-title":"Functional involvement of multidrug resistance-associated protein 4 (MRP4ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir.","volume":"71","author":"Imaoka","year":"2007","journal-title":"Mol Pharmacol"},{"key":"R43-13-20210202","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/bdd.1794","article-title":"Pharmacokinetic profiling of efavirenz-emtricitabine-tenofovir fixed dose combination in pregnant and non-pregnant rats.","volume":"33","author":"Nirogi","year":"2012","journal-title":"Biopharm Drug Dispos"},{"key":"R44-13-20210202","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/12487","article-title":"MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs.","volume":"5","author":"Schuetz","year":"1999","journal-title":"Nat Med"},{"key":"R46-13-20210202","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/01.qai.0000225013.53568.69","article-title":"Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study.","volume":"42","author":"Anderson","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R48-13-20210202","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/01.qai.0000243103.03265.2b","article-title":"Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavirritonavir.","volume":"43","author":"Kearney","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R49-13-20210202","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1086\/524061","article-title":"Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy.","volume":"197","author":"Goicoechea","year":"2008","journal-title":"J Infect Dis"},{"issue":"Pt 1","key":"R51-13-20210202","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1113\/jphysiol.2005.104430","article-title":"Evidence for altered placental blood flow and vascularity in compromised pregnancies.","volume":"572","author":"Reynolds","year":"2006","journal-title":"J Physiol"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000000747","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T21:00:09Z","timestamp":1748379609000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201508000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000000747","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]}}}